IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing including drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilities meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

 

Our Awards

CMO Leadership Award 2021

Service

CMO Leadership Award 2021

Reliability

PharmaTech Outlook

2020

Focus Innovation Award

2020

Twitter
@IDT Biologika

Thursday, 8. April 2021

IDT Biologika has laid the foundation stone for further capacities for the manufacture of active ingredients for va… https://t.co/BhOXDczrNX more info

Tuesday, 30. March 2021

https://t.co/8u4hWCH9cY more info

Tuesday, 23. March 2021

https://t.co/Pc8x8crriW more info

Monday, 15. March 2021

IDT Biologika is now using capacities at its Dessau site previously reserved for Takeda Pharmaceutical Company's de… https://t.co/NZS82Asa1C more info

Thursday, 4. March 2021

As a contract manufacturer of vaccines for the worldwide protection of people against infectious diseases, we act e… https://t.co/T39lAVerfr more info

Sunday, 14. February 2021

This year sees IDT Biologika celebrate its 100-year anniversary. The focus of the Bacteriological Institute of the… https://t.co/ICvWAWmaLU more info

Friday, 12. February 2021

Game changer spotted. Visual inspection activities at IDT Biologika have been made easier by setting up new inspect… https://t.co/7kX1F3DwLX more info

Wednesday, 10. February 2021

Vaccine manufacturer IDT Biologika will jointly invest in additional production capacities at its headquarters in D… https://t.co/5eVYvKmiSx more info

Thursday, 21. January 2021

IDT Biologika received two of Outsourced Pharma and Life Science Leader’s CMO Leadership Awards 2021 in the categor… https://t.co/ImYRunraKV more info

IDT Biologika lays foundations for new multifunctional vaccine production building

Thursday, 8. April 2021

Overall, a total of 100 million euros are currently being invested in the site... more info

IDT Biologika and Takeda support production of the Johnson & Johnson single-shot COVID-19 vaccine

Monday, 15. March 2021

Takeda provides booked capacity at the IDT site in Dessau more info

Start of second study phase of vector vaccine against COVID-19 postponed

Monday, 11. January 2021

Initial data for corona vaccine indicate good tolerability but weak immune response more info

Federal Minister of Health visits IDT Biologika

Tuesday, 24. November 2020

5 million vaccine doses against COVID-19 more info

IDT Biologika receives official notification of funding from the Federal government

Thursday, 8. October 2020

IDT Biologika receives official notification of funding from the Federal government more info